Dr. Ruthie Amir graduated from Ben Gurion University Medical School in 1989. From 1996-2000, she completed her post-doctoral fellowship in the Department of Human Genetic, at Baylor College of Medicine, Houston, USA where she worked on the genetic basis of Rett Syndrome. Between 200-2003 she completed a post-doctoral fellowship in the Department of Cell Biology, Faculty of Medicine, Technion. From 2008-2017, she served as the director of clinical research and the head of the regulatory department of Syneron Candela. In 2018, Dr. Ruthie Amir joined Alon-Medtech Ventures and as the chief medical officer.